Dr. Limor Chen – VP Operations & Clinical Affairs
PhD Immunology, Weizmann Institute | Cancer Research Fellow, MD Anderson Cancer Center | Post-Doctorate, Sunnybrook Hospital at University of Toronto | Masters of Science, Ben-Gurion University
Dr. Limor Chen brings 15 years of experience in R&D leadership in academia and in the pharmaceutical industry in North America and in Israel, dealing with scientific and business aspects of drug development.
He served as a Senior Researcher and Team Leader at Teva leading a team within the Special Projects Division. Most recently, Dr. Chen worked as Head of Business Development for an Israeli biotech which was successful in listing on the NASDAQ. Dr. Chen earned his Ph.D. at Israels Weizmann Institute of Science, in the laboratory of Prof. Ruth Arnon, the developer of Teva’s blockbuster Copaxone against Multiple Sclerosis.
He was a Research Fellow at the MD Anderson Cancer Center in Houston, and at the Sunnybrook Research Institute in Toronto.
Dr. Saeid Babaei – Chairman
PhD, Immunology, U of Toronto | Executive MBA, University of Toronto
Dr. Babaei has over 20 years of experience in leadership roles in the biopharmaceutical industry. He is currently President, & CEO of AbCelex Technologies with a proprietary antibody-based platform technology for animal health and human diagnostics. Prior to AbCelex, Dr. Babaei has served as Vice President of Business Development at Aptose Biosciences where he played a key role in a broad range of activities including establishing joint ventures, obtaining private financings, investor relations, and business development. He successfully negotiated a partnership deal for Virulizin, a cancer immunotherapy product candidate to Zor Pharmaceuticals, a subsidiary of Zoticon Bioventures. Previously, Dr. Babaei’s served as Director of Corporate Development at Northern Therapeutics Inc, a biopharmaceutical company which develops novel cell and gene therapies, where he was instrumental in launching the ‘first’ cell-based gene therapy clinical trial for patients with pulmonary arterial hypertension. He played key roles in obtaining financings, and in securing a partnership deal with United Therapeutics. Dr. Babaei currently serves as Chairman of the Board for BriaCell Therapeutics, an immuno-oncology biotech focused on late-stage breast cancer.
Dr. Benjamin Chen – Director
Cancer Research Fellow, Stanford | PhD, Immunology, U Wisconsin | MSc, Immunology, U Wisconsin | BSc, Bacteriology, U Wisconsin | Inventor on 7 patents, Published 64 times
Dr. Benjamin Chen was a Managing Director at Burrill & Co, a global life sciences merchant bank. Dr. Chen held an R&D leadership role at SyStemix, which was acquired by Novartis. In addition, he was instrumental in Sentinel Biosciences which was acquired by Roche.
Dr. Riva Kovjazin, M.D – Senior Scientist
M.D., Perm State School of Medicine | Immunology Research Fellow, Rostov Research Institute | Research Fellow, Center for Clinical Immunology, Moscow School of Medicine
Dr. Riva Kovjazin is an expert in the field of immunology with over 25 years of experience in cellular immunology. She obtained her M.D. from the Perm State University School of Medicine, one of the oldest universities in Russia. Dr. Kovjazin then specialized in the advanced study of immunology and epidemiology of conventional infectious diseases at the Rostov Research Institute. In addition, she was a project leader at the Center for clinical immunology, University of Medicine, Moscow, Russia where she studied Clinical immunology and diagnosis aspects of HIV. From 1997 until 2007, Dr. Kovjazin held various positions at XTL Biopharmaceutical